MarginsXMarginsX
Home › Markets › Health Care › SLS

SELLAS Life Sciences Group Inc. (SLS)

SLS trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$7.47
-4.96% on the day
Market cap
$1.5B
Small cap
Revenue · 2023
$0
-100.0% on 2022
Net income · 2023
-$37.3M

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2023-12-31, https://www.sec.gov/Archives/edgar/data/1390478/000139047824000004/0001390478-24-000004-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2023-12-31.

Profile

FieldValue
TickerSLS on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO yearNot reported by the screener
SEC CIK0001390478

Financials · 2023

LineValue
Revenue$0
Net income-$37.3M
Operating income-$37.9M
Net marginNeeds revenue and net income
Operating marginOperating income not reported
Revenue growth-100.0%
Cash$2.5M
Total assets$6.2M
P/E (computed)Net income was not positive
P/S (computed)Needs market cap and revenue

Warning signs

Cash runway
59.2 months
$134.7M cash at September 30, 2026
Share count, 1 year
+43.1%
2025-11-11 to 2026-11-11 · +535.8% over 3 years
Going-concern doubt
No
10-Q filed November 12, 2026
Insider net buying, 12 months
$101K
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.
"In accordance with Accounting Standards Codification ("ASC") 205-40, Presentation of Financial Statements - Going Concern , the Company evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about its ability to continue as a going concern within one year after the consolidated financial statements are issued."
10-Q 2026-11-12
Cash and burn$134.7M cash; operating cash flow -$6.8M a quarter.Report 2026-09-30
Shares outstanding203,859,151 (2026-11-11); 142,442,239 a year earlier; 32,062,258 three years earlier.Cover page 2026-11-11
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months1 S-3/F-3 shelf filings; 0 424B5 takedownsLatest 2026-03-20
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorBaker Tilly US, LLP, San Jose, California, United States; changed auditors 1 time in 24 months8-K 4.01 2025-06-06
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $101K, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$0-$10.1M-$5.9M$134.7MNo debt tagsNeeds four quarters10-Q 2026-11-12
Q2 2026
2026-06-30
Not filed-$9.6M-$7.6M$138.3MNo debt tagsNeeds four quarters10-Q 2026-08-11
Q1 2026
2026-03-31
Not filed-$8.4M-$8.8M$107.1MNo debt tagsNeeds four quarters10-Q 2026-05-12
Q4 2025
2025-12-31
Not filed-$7.7M-$4.9M$71.8MNo debt tagsNeeds four quarters10-K 2026-03-19
Q3 2025
2025-09-30
$0-$6.8M-$7.1M$44.3MNo debt tagsNeeds four quarters10-Q 2026-11-12
Q2 2025
2025-06-30
Not filed-$6.6M-$7.3M$25.3MNo debt tagsNeeds four quarters10-Q 2026-08-11
Q1 2025
2025-03-31
Not filed-$5.8M-$9.1M$28.4MNo debt tagsNeeds four quarters10-Q 2026-05-12
Q4 2024
2024-12-31
Not filed-$6.7M-$7.2M$13.9MNo debt tagsNeeds four quarters10-K 2026-03-19

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

The SEC filing list did not load in time for this page. It is on SEC EDGAR and in the full dossier.

Price moves

WindowReturn
1 week-6.7%
1 month-36.7%
3 months-36.4%
Year to date+108.5%
1 year+438.4%
From 52-week high-49.2%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
QUREuniQure N.V.$21.88-8.11%$1.5B
PGENPrecigen Inc.$4.30-5.29%$1.5B
ADRXADARx Pharmaceuticals Inc.$14.00-1.41%$1.6B
KRSAKorsana Biosciences Inc.$32.68+3.25%$1.5B
RAPPRapport Therapeutics Inc.$24.82-5.09%$1.5B
PCRXPacira BioSciences Inc.$36.48+0.05%$1.5B
NBTXNanobiotix S.A.$28.54-6.90%$1.5B
NRIXNurix Therapeutics Inc.$14.73-4.84%$1.6B

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier